Abbott Launches First-Ever Glucose Monitor For Non-Diabetics

 Abbott Laboratories (ABT) launched its newest continuous glucose monitor in the U.S. on Thursday. The biosensor named Lingo is the first-ever targeted for people without diabetes.

The move follows the launch of Dexcom's (DXCM) newest CGM, Stelo, last week. Stelo is targeted to people with prediabetes and type 2 diabetes who don't use insulin. But it's available over the counter, so people without diabetes will undoubtedly use it.

Olivier Ropars, divisional vice president of Abbott's Lingo business, says the company's move into metabolic health tracking is "genuinely transformative." Body-worn continuous glucose monitors, or CGMs, have long been a mainstay in tracking glucose for people with diabetes. But Lingo is for non-diabetics.

"It means a revolution in health overall," Ropars told Investor's Business Daily. "A strong decline in chronic disease over time. A better allocation of resources in the health care system. What we're talking about here is by giving these tools to the general population. We are finally investing in true health care — caring and managing health, not sick care."

https://www.investors.com/news/technology/abbott-laboratories-lingo-cgm-metabolic-health/